Leading a new era in radiopharmaceuticals

Telix is a  commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.

Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Clinical Pipeline

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline  

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix®

Illuccix®

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix®  

Join our team driving innovation across cancer and rare diseases.

View opportunities

Careers at Telix

Join our team driving innovation across cancer and rare diseases.

View opportunities   

Latest News

See all

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer – a broad clinical label. This approval enhances the options available to healthcare providers across Greece…

Read more

Telix Launches New Prostate Cancer Imaging Agent, Gozellix®, in U.S.

Read more

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany

Read more

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Portugal

Read more